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Abstract
The aim of our study was to analyze the differential expression of miRNAs in the brains of BSE-
infected cynomolgus macaques as a model for Creutzfeldt-Jakob disease (CJD). MicroRNAs
(miRNAs) are small noncoding RNAs regulating gene expression by mRNA targeting. Among other
functions they contribute to neuronal development and survival. Recently, the lack of miRNA
processing has been shown to promote neurodegeneration and deregulation of several miRNAs
has been reported to be associated with Scrapie in mice. Therefore, we hypothesized that miRNAs
are also regulated in response to human prion disease. We have applied miRNA-microarrays to
identify deregulated miRNA candidates in brains of BSE-infected macaques. Shock-frozen brain
sections of six BSE-infected and five non-infected macaques were used to validate regulated miRNA
candidates by two independent qRT-PCR-based methods. Our study revealed significant
upregulation of hsa-miR-342-3p and hsa-miR-494 in the brains of BSE-infected macaques compared
to non-infected animals. In a pilot study we could show that hsa-miR-342-3p was also upregulated
in brain samples of human type 1 and type 2 sporadic CJD. With respect to the reported regulation
of this miRNA in Scrapie-infected mice, we propose that upregulation of hsa-miR-342-3p may be a
general phenomenon in late stage prion disease and might be used as a novel marker for animal and
human TSEs.
Findings
Transmissible spongiform encephalopathies (TSE) com-
prise a group of neurodegenerative diseases including
bovine spongiform encephalopathy (BSE) in cattle,
Scrapie in sheep, and Creutzfeldt-Jakob disease (CJD) in
humans [1]. The causative agent is or is closely related to
a pathogenic isoform of the cellular prion protein (PrPc).
It is generally assumed that the alpha-helix-rich isoform
changes conformation to form the beta-sheet-rich coun-
terpart, PrPSc [2]. Aggregation of PrPSc coincides with neu-
ronal loss that finally leads to death of the host. The
molecular mechanism underlying prion-induced neuro-
degeneration is still poorly understood.
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Several lines of evidence indicate that microRNAs (miR-
NAs) may play a pivotal role in neurodegeneration [3,4].
MiRNAs are derived from primary transcripts (pri-
miRNA) that are sequentially processed into their mature
form by the RNase III type nucleases DROSHA and DICER
[5]. Incorporation of miRNAs in RNA-induced silencing
complexes (RISCs) then leads to decay or to translational
repression of complementary mRNA targets.
Loss of DICER activity has been linked to cerebellar
degeneration, neurotoxicity, and ataxia in Drosophila and
mice [6,7]. Furthermore, a role for miRNAs was also
described for neurodegenerative diseases in humans, such
as Morbus Parkinson [8], Chorea Huntington [9] and
Alzheimer's disease [10]. Most recently, the regulation of
endogenous miRNAs has also been linked to animal
prion disease [11]. Thus we hypothesized that miRNA reg-
ulation may also play a role in human prion diseases. To
investigate whether prion-induced neurodegeneration is
linked to deregulation of miRNA in the brain of affected
individuals, we analyzed differential miRNA expression in
brains of BSE-infected non-human primates (Macaca fas-
cicularis) as a model for Creutzfeldt-Jakob disease in
humans.
Previous studies have shown that the clinical course of
disease and the lesion profile in the central nervous sys-
tem of BSE-infected macaques are comparable to acquired
human CJD [12]. The tissues used for our study were
derived from six age- and sex-matched M. fascicularis
intracerebrally infected with brain homogenate from BSE-
infected cattle. Upon disease progression, BSE-affected
macaques displayed ataxia and tremors as first signs of
neuronal defects. Euthanasia was indicated by three or
more of the following clinical observations: loss of hand-
eye coordination, dehydration, myoclonus, apathy. PrPSc
aggregates in the brains of BSE-infected macaques were
confirmed using biochemical and immunohistochemical
methods according to established protocols [13]. Detailed
results of the on-going risk assessment study will be
reported elsewhere.
For the identification of deregulated miRNAs we applied
miRNA microarrays which have been widely used to ana-
lyze miRNA expression patterns. For our approach we
have used shock-frozen biopsy punches of the basis pontis
region of one BSE-diseased and one non-infected
macaque. The miRNA was enriched using a commercially
available kit (Ambion) according to the supplier's instruc-
tions. Labeling of the microRNA was achieved by poly-
uracil tailing and subsequent covalent linkage of a fluores-
cent dye (DY647, MoBiTec) according to a published pro-
tocol [14]. The labeled RNA was probed on microarray
slides (Codelink, Amersham) spotted with 352 unique
antisense miRNA oligonucleotides covering a wide range
of currently known miRNA sequences from rats, mice,
and humans (probeset 1564V1, Ambion). Microarrays
were processed according to published protocols [15]. The
fluorescence data were generated according to the MIAME
guidelines and deposited in the Gene Expression Omni-
bus (GEO) database at http://www.ncbi.nlm.nih.gov/geo
(accession number GSE12651).
To date, no miRNA-expression profile of brain from
cynomolgus macaques has been published. Therefore, we
first examined the basal miRNA expression and compared
it to that of human brain. Correlation of the endogenous
macaque miRNA expression pattern with published
human brain miRNA profiles [16-18] revealed that the
microarray setup was suitable for miRNA profiling in
macaque brain as a model for human miRNA expression
(additional file 1). We therefore assumed that BSE infec-
tion of cynomolgus macaques represents an appropriate
model to predict miRNA regulation in acquired human
CJD.
Thus, we performed a miRNA microarray analysis of brain
samples derived from a BSE-infected and a non-infected
macaque. Alterations in miRNA expression levels were
only examined post mortem. Earlier stages could not be
assessed due to the very limited number of experimental
animals. Analysis was performed in a two-color dye swap
design with six technical replicates. We identified 21 out
of 275 human miRNAs that were up- or downregulated
more than twofold. Differential expression was detected
for both, high and low abundant miRNAs (Table 1). We
excluded those miRNAs from further analysis showing
divergent endogenous expression levels as compared to
human brain, e.g. hsa-miR-103 and -107 (additional file
2) and the abundantly expressed members of the let-7
family.
To validate our initial analysis we examined the regula-
tion pattern in detail using a highly sensitive and quanti-
tative approach. The relative expression of selected
miRNA candidates hsa-miR-26a, hsa-miR-124a, hsa-miR-
143, hsa-miR-145, hsa-miR-342-3p, and hsa-miR-494
were validated by quantitative reverse transcription PCR
(qRT-PCR) analysis using a higher number of animals.
MiRNA derived from brain samples of six BSE-infected
cynomolgus macaques was compared to five age- and sex-
matched controls. Five nanograms of the miRNA-
enriched fraction derived from each of the eleven animals
were used for stem-loop qRT-PCR according to the sup-
plier's instructions (TaqMan MicroRNA Assay, Applied
Biosystems) in a 7500 Real Time PCR System (Applied
Biosystems). Individual samples were tested for the
expression of the miRNA candidates in relation to the
ubiquitously expressed small nucleolar RNA RNU66 that
served as a housekeeping gene. Using this technique weMolecular Neurodegeneration 2009, 4:36 http://www.molecularneurodegeneration.com/content/4/1/36
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could confirm the upregulation of hsa-miR-26a, -342-3p
and -494 in the brain of six BSE-infected macaques com-
pared to five non-infected controls (Figure 1A). The indi-
vidual control animals showed comparable expression
levels for each miRNA (additional file 3).
Since the mature forms of hsa-miR-342-3p and miR-494
reside on the 3'-arm of the pre-miRNA the stem-loop qRT-
PCR cannot distinguish between DICER processed or
unprocessed forms. In addition, the use of independent
cDNA syntheses for each miRNA is likely to cause sample
variation. Thus, we decided to use a second qRT-PCR-
based assay (poly(A)-tailed qRT-PCR). The relative expres-
sion of microRNAs from each individual macaque was
determined by poly(A)-tailing, cDNA-synthesis and sub-
sequent qRT-PCR according to published procedures [19]
with minor modifications. In brief, 100 ng of enriched
miRNA fraction was polyadenylated according to the sup-
plier's protocol (A-Plus™ Poly(A) Polymerase Tailing Kit,
Epicentre) and reverse transcribed using a polyT-primer
coupled to a unique sequence tag at its 5'-end. Quantita-
tive reverse transcription PCR was performed with
miRNA-specific forward primers for hsa-miR-26a, hsa-
miR-342-3p, hsa-miR-494 or the small nucleolar RNA
RNU66, respectively, and a universal reverse primer iden-
tical to the cDNA sequence tag (Figure 1B). Significant
upregulation of hsa-miR-26a in BSE-infected macaques
could not be confirmed using this independent method.
However, our analysis revealed that both miRNAs, hsa-
miR-342-3p and hsa-miR-494, were significantly upregu-
lated in BSE-infected macaques (Table 1). Therefore, we
could show that two miRNAs were upregulated in a non-
human primate model for human prion disease.
Since miRNAs regulate their respective target genes via
binding to specific seed regions in the 3'-UTR we exam-
ined the set of bioinformatically predicted mRNA-targets
using a public prediction program (TargetScan, [20]).
Beside others, putative target genes involved in neurode-
generative diseases were found for both, hsa-miR-342-3p
and hsa-miR-494. Those genes are involved in protein
aggregation disorders, such as tauopathies, Chorea Hunt-
ington, and spinocerebellar ataxia (additional file 4). We
also perceived that hsa-miR-494 is deregulated in different
types of cancer [21-23], and upregulated in a rat model for
type 2 diabetes [24].
Most intriguingly, Saba and colleagues examined the
miRNA profile of Scrapie-infected mice [11]. In order to
determine coincidences in the miRNA regulation patterns
of both, Scrapie infection in mice and BSE infection in
non-human primates, we correlated the miRNA expres-
Table 1: Differentially expressed miRNAs in the brain of BSE-infected macaques and their relative abundance in the basis pontis region 
of macaque brain
Regulated miRNAs identified by 
microarray
relative abundance in macaque brain
[% of highest expressed miRNA]
regulation factor
microarray stem-loop qRT-PCR Poly(A)-tailed qRT-PCR
hsa-miR-26a 83,4 3.0 ** 1.0
hsa-miR-30a-5p 1,2
hsa-miR-30d 10,6
hsa-miR-103 27,1
hsa-miR-106b 9,0
hsa-miR-107 41,3
hsa-miR-124a 58,4 2.2
hsa-miR-125a 23,6
hsa-miR-128a 22,8
hsa-miR-132 11,3
hsa-miR-143 8,2 0.5
hsa-miR-145 13,9 0.6
hsa-miR-181a 26,3
hsa-miR-191 13,9
hsa-miR-195 4,9
hsa-miR-219 1,3
hsa-miR-320 6,9
hsa-miR-342-3p 8,0 2.7 *** 1.13 ***
hsa-miR-361 8,7
hsa-miR-490 3,6
hsa-miR-494 2,1 3.7 *** 8.1 ***
** student t-test with Welch's correction; p < 0.01,
*** student t-test with Welch's correction; p < 0.001Molecular Neurodegeneration 2009, 4:36 http://www.molecularneurodegeneration.com/content/4/1/36
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Deregulated miRNAs in the brainof BSE-infected macaques identified by qRT-PCR analysis Figure 1
Deregulated miRNAs in the brainof BSE-infected macaques identified by qRT-PCR analysis. The basis pontis 
region of six BSE-infected and five non-infected macaques were dissected, miRNAs were isolated and 5 ng each analyzed for 
differential miRNA expression. A. MiRNA regulation according to stem-loop qRT-PCR (Applied Biosystems) and B. using 
poly(A)-tailed qRT-PCR. Analyses were performed twice in duplicate for each animal. Differential expression was analyzed by 
the ΔΔCT method [27] using the small nucleolar RNA RNU66 as a housekeeping RNA and the non-infected animals as calibra-
tors. Statistical analysis was performed using unpaired t-test with Welch's correction (** p < 0.01, *** p < 0.001). n.d., not 
done. Shown are the mean regulation factors ± SD of all infected animals.
hsa-miR-26a
hsa-miR-124a
hsa-miR-143
hsa-miR-145
hsa-miR-342-3p
hsa-miR-494
0.5
1
2
4
8
** ***
***
f
o
l
d
 
c
h
a
n
g
e
hsa-miR-26a
hsa-miR-124a
hsa-miR-143
hsa-miR-145
hsa-miR-342-3p
hsa-miR-494
0.5
1
2
4
8
16
n.d. n.d. n.d.
***
***
f
o
l
d
 
c
h
a
n
g
e
A
BMolecular Neurodegeneration 2009, 4:36 http://www.molecularneurodegeneration.com/content/4/1/36
Page 5 of 7
(page number not for citation purposes)
sion patterns derived by miRNA-microarray. Even though
several miRNAs were regulated in only one of both infec-
tion models the miRNA expression profiles showed a sta-
tistical significant correlation (Spearman, p < 0.05; Figure
2A). Among others, such as hsa-miR-191, hsa-miR-200b,
hsa-miR-320 and several members of let-7 family we
found that hsa-miR-342-3p was regulated at a late stage of
disease in both, Scrapie-infected mice and BSE-infected
macaques. It should be noted that only a very small region
of the brain, i.e. basis pontis, was used for our analysis in
non-human primates as compared to whole brain of
Scrapie-infected mice. This may be reflected by the
detected differences in regulation patterns. However, the
comparable regulation of hsa-miR-342-3p may apply to
prion disease in general. We concluded that upregulation
of this particular miRNA may be a general marker candi-
date for late-stage prion disease or neurodegeneration. In
this case hsa-miR-342-3p would also be upregulated in
human prion disease. To strengthen our hypothesis we
assessed the regulation of miR-342-3p in brains of spo-
radic Creutzfeldt-Jakob disease (sCJD) patients. In con-
trast to the experimentally induced prion disease in
macaques, human sCJD occurs idiopathically. Depending
on the age of onset, disease course, plaque formation,
affected brain regions and biochemical properties of the
prion protein aggregates human sCJD has been classified
into two different types [25]. The miR-342-3p expression
in the brains of a sCJD type 1 and a sCJD type 2 patient
compared to a non-infected individual was analysed by
qRT-PCR. MiRNA was enriched as described for simian
brains and applied to stem-loop qRT-PCR for hsa-miR-
342-3p. Data were normalized against the ubiquitously
expressed small nucleolar RNA RNU48. Our pilot study
revealed that hsa-miR-342-3p was upregulated approxi-
mately 2-fold in sCJD type 1 and 1.5-fold in sCJD type 2,
respectively (Figure 2B) at a comparable level as in BSE-
infected macaques.
Although regulation of hsa-miR-342-3p was not observed
in miRNA studies using brain samples from Alzheimer's
[26], or Huntington's disease [9] patients, we cannot rule
out that this miRNA is not exclusively upregulated in
prion-induced disorders. Thus the suitability of hsa-miR-
342-3p as a novel biomarker for TSEs in animals and
humans has to be further investigated. Future studies also
have to reveal whether hsa-miR-494 is also upregulated in
other prion disorders.
The presented conclusions rely on a considerable, but low
number of experimental animals. In addition, we only
assessed the expression of hsa-miR-342-3p in two sCJD
patients which was compared to one healthy control.
However, given that hsa-miR-342-3p was found in two
experimental animal models and in human Creutzfeldt-
Jakob disease, we assume that this miRNA may play a gen-
Regulation of miRNA hsa-miR-342-3p in different prion dis- orders Figure 2
Regulation of miRNA hsa-miR-342-3p in different 
prion disorders. A. Regulation of miRNAs upon BSE infec-
tion in cynomolgus macaques compared to the published 
miRNA profile of Scrapie infection in mice. 500 ng miRNA 
enriched fraction from a BSE-infected and a non-infected rhe-
sus macaque were fluorescently labeled and applied to 
miRNA microarray (Probeset 1564V1, Ambion). Regulation 
of each miRNA was calculated from the relative fluorescence 
values of the infected versus the non-infected animal. 
Acquired miRNA regulation profile was compared to a pub-
lished profile derived from Scrapie-infected mice [11]. Cor-
relation of both regulation profiles was statistically significant 
(Spearman correlation, p < 0.05). Relevant miRNAs regu-
lated above twofold in both arrays are marked by an open 
square. B. Regulation of miR-342-3p in samples derived from 
brains of patients with type 1 sCJD, type 2 sCJD and a 
healthy control, respectively. 5 ng miRNA were applied to 
qRT-PCR specific for hsa-miR-342-3p (stem-loop qRT-PCR, 
Applied Biosystems). Relative miRNA expression was ana-
lyzed by ΔΔCT method [27] using the small nucleolar RNA 
RNU48 as a housekeeping RNA and the healthy human con-
trol as a calibrator. Statistical significance was determined by 
student-t-test (non-parametric with Welch's correction, *** 
p < 0.001). The mean regulation factor ± SD of duplicates 
from two independent experiments are shown.
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eral role in the regulation of multiple target genes in late-
stage prion disease. Analysis of the respective target genes
in the central nervous system might be used as a tool to
gain new insights in the molecular mechanism of neuro-
nal decay.
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